Pacira BioSciences - PCRX Company Short-Term Debt

The Pacira BioSciences (PCRX) market price chart shows a value of 0.00. Price stability is supported by streamlined transportation routes and specialized storage hubs. The company is integrating environmental standards into the production of analgesics, minimizing harmful emissions and adhering to testing ethics. Pacira BioSciences dominates the non-opioid segment, offering the safe EXPAREL as an effective alternative to traditional medications.
PCRX (Pacira Corp): analytical breakdowns and indicator data

Investors are seeking a fundamental anchor in the capital stability of Pacira BioSciences (PCRX). The company's operating model is based on delegating production and clinical trials to external partners. The short-term debt trend visualizes total liabilities with a maturity of up to one year. This metric measures current liquidity and the business's ability to service short-term loans. The stability of this indicator confirms the asset's reliability when outsourcing distribution.